SNAI1 and non-small cell lung carcinoma: Collectively, this study provided preclinical support for using capmatinib for the treatment of osimertinib-resistant NSCLC cells, by ways of inhibiting MET/Akt/Snail signaling and CAF transformation (Figure 6).